<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03449056</url>
  </required_header>
  <id_info>
    <org_study_id>OPTINEB</org_study_id>
    <nct_id>NCT03449056</nct_id>
  </id_info>
  <brief_title>High-flow Nasal Cannula Nebulization of Beta 2 Adrenergic Agonist During Acute Exacerbation of Chronic Obstructive Pulmonary Disease</brief_title>
  <acronym>OPTINEB</acronym>
  <official_title>High-flow Nasal Cannula Nebulization of Beta 2 Adrenergic Agonist During Acute Exacerbation of Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      High-flow nasal cannula is an oxygenation technique increasingly used for patients admitted&#xD;
      for acute respiratory failure. Literature essentially concerns &quot;de novo&quot; acute hypoxemic&#xD;
      failure and the interest of high-flow during take care of chronic obstructive pulmonary&#xD;
      disease patients is few studied. Physiological studies reported potential benefits of&#xD;
      high-flow nasal cannula oxygenation in chronic obstructive pulmonary disease patients&#xD;
      including dead space clearance and decrease of respiratory, which lead to decrease work of&#xD;
      breathing. As inhaled bronchodilators are part of treatment of chronic obstructive pulmonary&#xD;
      disease exacerbation, nebulization could be also provided through high-flow nasal cannula&#xD;
      oxygen therapy. The aim of our study is to determine whether a beta-2 agonist nebulization&#xD;
      administered through High-flow nasal cannula is efficient to improve spirometry of patients&#xD;
      for admitted hronic obstructive pulmonary disease exacerbation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">January 11, 2019</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>compare lung functions</measure>
    <time_frame>baseline-1h30</time_frame>
    <description>Evolution of Forced Expiratory Volume 1s</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <condition>High-flow Nasal Cannula</condition>
  <arm_group>
    <arm_group_label>TREATMENT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>salbutamol nebulization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>salbutamol</intervention_name>
    <description>T2 - T1+1h30: High-nasal flow and salbutamol nebulization</description>
    <arm_group_label>TREATMENT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Arterial pH over 7.25,&#xD;
&#xD;
          -  Respiratory rate under 35 breaths/mn&#xD;
&#xD;
          -  Glasgow Coma Scale equal to 15,&#xD;
&#xD;
          -  indication of beta-2 agonist nebulization less than 8 per day (time between two&#xD;
             nebulization more than 3 hours),&#xD;
&#xD;
          -  NIV sessions spaced more than 6 hours.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Urgent endotracheal intubation;&#xD;
&#xD;
          -  Contraindication to beta 2 adrenergic agonist;&#xD;
&#xD;
          -  Another organ failure (hemodynamic and neurological instability);&#xD;
&#xD;
          -  Cardioselective beta-blocker during treatment of copd exacerbation;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean-Pierre FRAT</last_name>
    <phone>+33549442830</phone>
    <email>jean-pierre.frat@chu-poitiers.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>nicolas MARJANOVIC</last_name>
    <email>nicolas.marjanovic@chu-poitiers.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>C.H.U. de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre Frat, MD</last_name>
      <email>jean-pierre.frat@chu-poitiers.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>January 12, 2018</study_first_submitted>
  <study_first_submitted_qc>February 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2018</study_first_posted>
  <last_update_submitted>February 11, 2019</last_update_submitted>
  <last_update_submitted_qc>February 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

